About Dr. Henry Sun
In the past 10 years, Dr. Sun leads his group successfully registered over 20 new drugs in 32 countries, and made a historical milestone to develop a multi-herbal drug product to its clinical phase III stage in the United States. His view of Tasly is to bring this top China based Pharma to become a global company in the next 10 years. His current interests are the development of innovative drugs, research in regulatory policy and clinical pharmacology, and promotion of translational medicine.
Dr. Sun is also a professor and department chairman at the School of Pharmaceutical Science and Technology, Tianjin University, China; and a special professor at the School of Medicine of Nottingham University, Nottingham, UK.